Introduction
Diabetic macular edema (DME) is one of the manifestations of diabetic retinopathy leading to loss of central vision and visual acuity.
2 DME results from microvascular changes in the retina in both type 1 and type 2 diabetes mellitus.
3 DME is defined as thickening located within two disc diameters of the center of the macula. When this is present within or close to the central macula, it is termed clinically significant macular edema (CSME). 4 DME is further classified descriptively into focal and diffuse DME. Focal DME describes the edema from individual microaneurysms where as diffuse DME implies extensive or generalized leakage from the posterior capillary bed and breakdown of the inner blood-retinal barrier. Combinations of the two are frequent.
It is important to detect DME in the assessment of diabetic retinopathy as this is the most frequent cause of decreased vision from retinopathy. Both macular edema (ME) and CSME, defined by proximity of these signs to the foveal center, are best assessed using slit-lamp biomicroscopy or by grading stereoscopic macular photographs. Optical coherence tomography (OCT) may be also used to provide valuable confirmation and quantification of the clinical grading for DME and facilitate monitoring of its response to therapy. 4 This review is concerned with diabetic macular edema, both focal and diffuse. The treatment considered in this review is anti-vascular endothelial growth factor (anti-VEGF).
Epidemiology
Between 25% and 44% of people with diabetes have some form of diabetic retinopathy (DR) at any point in time. The United States National Eye Institute pooled data from eight well-conducted population-based studies of persons aged 40 years or older with consistent retinopathy grading from retinal photographs. Data included that from five United States (US) studies, one West Indian study, and two Australian studies (Blue Mountains Eye Study [BMES] and Melbourne Visual Impairment Project [MVIP] ). The overall crude DR prevalence was 40%. The prevalence of sight-threatening retinopathy (CSME or proliferative diabetic retinopathy [PDR]) was 8.2%. The general US population prevalence of DR and sight-threatening retinopathy were 3.4% (4.1 million persons) and 0.8% (900,000 persons), respectively. Projected to the current Australian population, these rates suggest a prevalence of 300,000 and 65,000, respectively, for any DR and sight-threatening retinopathy (PDR or CSME) in persons aged over 40 years. 4 
Clinical presentation and diagnosis
Blurred vision is the most common clinical presentation of DME, as well as distortion of the visual image (metamorphopsia), floaters, and changes in contrast sensitivity. Photophobia, changes in color vision, and scotoma occurs in DME while a loss of vision is associated with increased severity and progression of the disease. Chronic macular edema can be associated with cystoid macular edema.
Stereoscopic observation of the macular is considered the most acceptable way to diagnose DME, however use of OCT, stereofundus photography and fluorescein angiography have become acceptable tools for diagnosis in clinical practice. 5 
Treatment options
Strict glycemic control is the hallmark of prevention and halts progression of disease. Laser photocoagulation is used to coagulate tissue either by direct focal photocoagulation for focal macular edema or using grid photocoagulation for diffuse DME. The Early Treatment Diabetic Retinopathy Study (ETDRS) demonstrated that photocoagulation reduced the risk of moderate vision loss, especially for those eyes with macular edema that involved or threatened the center of the macular. 6 This has become a standard treatment in clinical practice. Steroids including intravitreal triamcinolone (IVT) or surgical implantation have increased in popularity for treatment of DME due to their angiostatic effects and antipermeabilty properties which minimize systemic toxicity. Vitrectomy is considered for treatment in eyes with chronic or diffuse DME that is not responsive to laser. 7 
Pathophysiology and intervention
Vascular endothelial growth factor (VEGF); also known as VEGF-A) has an important role in angiogenesis (ie, the migration and mitosis of endothelial cells) up-regulating methane monooxygenase and αvβ3 activity, and the creation of blood vessel lumen and fenestrations. As seen in preclinical models, VEGF has been shown to facilitate survival of existing vessels, contribute to vascular abnormalities (eg, tortuousness and hyper permeability) that may impede effective delivery of antitumor compounds, and stimulate new vessel growth. 8 VEGF has been shown to be an endothelial cell specific mitogen, an angiogenic inducer, and is also known to increase retinal vessel permeability. 2 Hypoxia-regulated VEGF release likely plays a key role in the normal development of the retina and, given its hypoxia inducibility, VEGF became an attractive candidate as a mediator of pathological intraocular neovascularization. Expression of VEGF messenger ribonucleic acid (mRNA) spatially and temporally correlates with neovascularization in several animal models of retinal ischemia. 33 Elevations of VEGF levels in the aqueous and vitreous humor of human eyes with proliferative retinopathy secondary to diabetes, and other conditions have been previously described.
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Anti-VEGF modalities have been shown to potently suppress angiogenesis and growth in a variety of human tumor cells lines and also to inhibit neovascularization of ischemic retinal disease.
Bevacizumab is a full-length humanized monoclonal antibody against VEGF 10 meaning it binds to all subtypes of VEGF. Pegaptanib is a synthesized anti-VEGF aptamer of a single ribonucleic acid strand that specifically targets VEGF-165 and binds only to it. Aptamers are oligonucleotide ligands that are selected for high-affinity binding to molecular targets. 11 Ranibizumab (rhuFab-VEGF) is an antibody fragment which neutralizes all VEGF isoforms and bioactive fragments.
Recent studies have demonstrated the usefulness of anti-VEGF in the reduction of macular edema secondary to central retinal vein occlusion, vascular permeability, and fibrovascular proliferation in retinal neovascularization secondary to PDR, and choroidal neovascularization secondary to aged-related macular degeneration (AMD). 12 
Rationale for a systematic review
Monoclonal antibodies against vascular endothelial growth factor (VEGF) were first developed in treatment of metastatic colorectal cancer. 13 Anti-vascular endothelial growth factor is now commonly used for age-related macular degeneration to halt progression of abnormal growth of blood vessels in the back of the eye. A Cochrane review of five RCTs concluded the use of two anti-VEGFs to reduce the risk of visual acuity loss in neovascular age-related macular degeneration.
14 More recently, these results have prompted trials in applying anti-VEGF in diabetic macular edema and macular edema secondary to central retinal vein occlusion.
In a 6-month follow-up study for anatomic and bestcorrected visual (BCVA) acuity after primary intravitreal bevacizumab (Avastin ® ) in patients with DME, Arevalo et al 2 showed improvements in visual acuity, OCT, and fluorescan angiography (FA) for all doses injected. Nguyen et al 1 showed promising results with ranibizumab (a specific antagonist of VEGF) in a nonrandomized clinical trial. Results showed intraocular injections of ranibizumab significantly reduced foveal thickness and improved visual acuity in 10 patients with DME.
In a retrospective review Chung et al 15 concluded a decrease in mean visual acuity score after three months in an ischemic subgroup (patients with an enlarged foveal avascular zone [FAZ] or broken perifoveal capillary ring at the border of the FAZ, with a distinct area of capillary nonperfusion).
Their findings indicate the use of anti-VEGF has a negative effect on short-term visual outcome in a particular subgroup of DME. DME continues to progress in spite of a lack of a gold standard treatment, although options of vitrectomy, laser photocoagulation, and the emerging popularity of intravitreal steroids have been shown to halt progression of disease.
Although the ETDRS demonstrated that immediate focal photocoagulation reduced moderate visual loss by 50% (from 24% to 12%, 3 years after initiation of treatment), 12% of treated eyes still lost 15 ETDRS letters at 3 year follow-up. Approximately 40% of treated eyes with retinal thickening involving the center of the macula at baseline still had thickening involving the center at 12 months. Only 3% of laser-treated eyes experienced a gain of 3 lines of vision. 6 Anti-VEGF provides an option to treatment for these patients and it may also be a very useful adjunctive treatment before laser or vitrectomy surgery or a potentially important role as an adjunct to laser in the management of DME. Recently, RCTs have been published and continued to examine various antiangiogenic therapies. There has been no systematic review published evaluating RCTs conducted with treatment of VEGF for DME. Given the disease burden and significance of vision in terms of quality of life, a systematic review is needed to examine the evidence regarding the effectiveness and safety of antiangiogenic therapy with anti-VEGF modalities for treatment of DME.
Objective
The objective of this review was to assess the effectiveness of antiangiogenic therapy with anti-VEGF modalities in the treatment of diabetic macular edema. Tables 1 and 2 show inclusion and exclusion criteria for the studies considered for this review. 
Data sources

Selection of studies
Screening of titles and abstracts resulting from electronic and manual searches were reviewed. Abstracts were classified as relevant, potentially relevant, or not relevant for this review. Full copies of abstracts were obtained for relevant and potentially relevant reviews. Abstracts and full reviews were read to determine inclusion. Only randomized clinical trials were eligible. Study findings are in concordance with the Quorom statement. Figure 1 illustrates this selection of studies with a flow diagram. Table 3 illustrates extracted data for the primary and secondary outcomes for this review.
Methods
Data extraction and management
Data synthesis
BCVA and central macular thickness (CMT), the primary outcome variables, are expressed as continuous variables. Standard deviations were calculated by Cunningham et al using actual P values obtained from t-tests quoted by Cochrane. 19 For every study, we calculated the mean difference for the primary outcome BCVA, LogMAR, and the CMT using 95% confidence intervals. The outcome measures were pooled by use of the fixed-effect model as there were only three trials used in the meta-analysis.
Heterogeneity was calculated using Cochran's Q statistic and quantified using the I 2 statistic. These indicated the proportion of variability across studies due to heterogeneity, rather than sample error. Despite a high I 2 , results were pooled as examination of these studies on a forest plot indicated that the individual trial results were consistent in the direction of the effect (ie, the mean difference and confidence intervals largely fell on one side of the null line).
Clinical heterogeneity was present between the studies in relation to dosage and type of anti-VEGF use. Treatment duration and follow-up varied from 12 to 36 weeks. Despite clinical heterogeneity, trials were pooled and overall efficacy from any type of dose or duration of anti-VEGF was assessed in the objectives. Subgroup analysis was not performed due to the limited trials. Characteristics of age, gender ratios, and baseline visual acuity were similar across all trials, however variability in trial quality and intervention type, dose, and timing of administration varied. Table 4 highlights the characteristics of the included studies. Asymmetry assessment of the funnel plot was not conducted for publication bias as only three trials were used in the final analysis. In future analyses, asymmetry of the funnel plot will be used to identify publication bias if at least seven studies are used. In the case of missing data, efforts to contact authors were made. Data was entered in Review Manager 5 (Cochrane, Sanfrancisco, CA) and fixed effect models were used.
Assessment of risk of bias in included studies has been considered using methods described in chapter 6 of the Cochrane Handbook for Systematic Reviews of Interventions. 19 The following parameters were assessed: randomization process, allocation concealment, and masking of participants and investigators. Table 4 offers a summary of included studies characteristics for trial quality assessment score.
Description of studies
Electronic searches conducted in July 2008 and October 2008 resulted in 279 abstracts with 28 abstracts reviewed. Of those, 15 full-texts were read and five were found to meet our eligibility criteria. The reference list of each of the 15 full-text articles was searched for other relevant articles. Nine studies were excluded. Table 4 provides a summary of included studies characteristics and the Appendix lists included and excluded studies. Eight publications were not RCTs and one did not mention DME with an intervention of vitrectomy surgery in the assessment and primary outcome measure.
To our knowledge, there are 10 ongoing clinical trials using anti-VEGF for treatment of DME. Authors and trial groups were contacted, but we were unable to obtain preliminary data. Cunningham et al 21 was funded by a pharmaceutical company (Pfizer).
Participants
We included five studies from three countries (United States, Iran, and Brazil) with a total of 525 eyes represented in the review. The range of eye enrollments in the trials varied with the largest study enrolling 172 eyes, 21 however this was a study with three intervention groups and one control group. The numbers of subjects within each group, therefore, become smaller (n = 42-44). The study by Paccola et al 24 was the smallest trial, enrolling 28 eyes.
Participants were male and female adults. All studies excluded patients who had undergone previous laser treatment at least 3-6 months prior. Soheilian et al 23 included patients without prior laser treatment, whereas Ahmadieh et al 20 and Paccola et al 24 included participants unresponsive to previous macula laser photocoagulation at least 3 months prior. The studies by both Scott et al 22 Dovepress macular edema and generally defined the edema as focal or diffuse and as persistent or refractory. All trials mentioned diabetic macular edema. None of the trials mention whether the patients also had cystic macular edema. All of the trials explicitly report the primary outcome factor of BCVA according to the ETDRS. CMT is reported in all the studies either at baseline to follow-up measurements or as a mean change in thickness, measured in µm. Duration of diabetes and baseline intraocular pressure (IOP) measurements were not explicitly mentioned in all the trials. Adverse events were described within trials. Scott et al 22 presented safety summary data on adverse event rates between groups, while Ahmadieh et al 20 and Soheilian et al 23 described percentages of adverse reaction rates amongst the different groups. Cunningham et al 21 listed adverse events among their subjects with pooled results for certain subgroups (eg, hypertension). Two-way analysis of variance was performed by Paccola et al 24 for raised IOP and description of adverse effects. Adverse events described were tabled see table of adverse events but data for analysis was not performed. 24 compared IVB to IVT interventions. Bevacizumab was employed in four studies and one study used pegaptanib. No studies were included using ranibizumab. Table 4 gives a summary of included studies characteristics.
Interventions
Outcome measures
All trials considered visual acuity using ETDRS charts and CMT using OCT as their major outcome. Definitions of visual acuity varied across the trials. BCVA was quantified in all trials. All trials used OCT to measure CMT in µm, however some studies reported CMT change whilst others reported mean baseline and follow-up results. CMT was quantified in all trials.
Adverse events of interest included: IOP increase reported in five trials; anterior chamber reaction reported in three trials; nil progression of leno pacification reported in all trials; iris neovascularization reported in three trials; Abbreviations: CSME, clinically significant macular edema; DME, diabetic macular edema; BCVA, best-corrected visual acuity; CMT, central macular thickness; IVB, intravitreal bevacizumab; IVP, intravitreal pegaptanib; VA, visual acuity.
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Methodological quality
Overall, three of the trials' 20-22 assessors were adequately masked. Intravitreal injections were masked in one 23 and there was masking for the measurement via OCT and fluorescein angiography in the other. 24 The fundus assessments were performed by two retina specialists who were aware of the treatment assignment. Study data were collected, interpreted, and analyzed by two other masked investigators. Intentionto-treat analysis was performed in three trials. 20, 21, 23 Randomization consisted of varying length of permuted blocks, simple randomization, and applying a dynamic minimization procedure using a stochastic treatment allocation algorithm based on a variance method. The process of randomization was described in one study, 24 but allocation concealment was not described in any of the trials.
In the Ahmadieh et al 20 study, one patient in the control group died during the study period. Cunningham et al 21 left out nine patients from the study as a result of one death and eight patient requests. Scott et al 22 had two subjects withdraw before completion of the study and their overall visit completion rate was 93%. Paccola et al 24 reported that two subjects missed two consecutive treatments, while Soheilian et al 23 reported no losses to follow-up.
Results
Meta-analysis of data was only possible for three trials. 20, 21, 23 We were unable to use data from one trial, 22 as results were expressed in medians and interquartile ranges. The authors have been contacted for their raw data, including means and standard deviations. This trial will be added to the metaanalysis once appropriate results obtained.
The study by Paccola et al 24 was not included in the metaanalysis as this study compared intravitreal bevacizumab to intravitreal triamcinolone instead of a control or standard therapy such as laser. The study by Paccola et al 24 has been included in the qualitative analysis of anti-VEGF.
It should be noted that with respect to the forest plots reported in this review, for outcomes such as gain in visual acuity and CMT, effect estimates to the right of the vertical line favor test treatment.
Anti-VEGF treatments were shown to have a benefit in improving BCVA. For instance, Cunningham et al 21 compared three differing doses of intravitreal pegaptanib compared to a control injection. Three forests plots each with a differing dose of pegaptanib showed a consistent benefit with the intervention on visual acuity. Using pegaptanib 0.3 mg in the meta-analysis, the mean change in visual acuity was -0.17 (95% confidence interval [CI]: -0.23, -0.10). A similar treatment effect was seen using 1 mg and 3 mg of pegaptanib with a mean difference of -0.17 (95% CI: -0.23, -0.10) and -0.14 (95% CI: -0.20, -0.07), respectively (Figures 2-4) .
Anti-VEGF therapy has a benefit on CMT. Cunningham et al 21 compared three differing doses of intravitreal pegaptanib to a control injection. Three forests plots, each demonstrating a differing dose of pegaptanib, showed a consistent benefit of the intervention on CMT. Using pegaptanib 0.3 mg in the meta-analysis, the mean change on CMT was found to be -84.69 (95% CI: 117.09, -52.30). A similar treatment effect was seen using 1mg and 3 mg of IVP with a mean difference -84.69 (95% CI: -117.09, -52.30) and -72.47 (95% CI: -106.67, -38.27) in evidence ( Figures 5-7) .
Combined anti-VEGF with intravitreal triamcinolone was shown to benefit both visual acuity and central macular thickness compared to the control. Mean difference for visual acuity 
Total (95% CI)
Heterogeneity: Chi² = 3.91, df = 2 (P = 0.14); I² = 49% Test for overall effect: Z = 5.12 (P < 0.00001) was -0.19 (95% CI: -0.27, -0.11) and the CMT mean change was -111.20 (95% CI: -148.13, -74.28) (Figures 8 and 9 ).
Mean
Scott et al 22 revealed a benefit in central macular thickness when using the intervention of 1.25 mg and 2.5 mg of intravitreal bevacizumab compared to the use of laser. There was only a trend towards reduction up to 12 weeks, however. Visual acuity also improved with the two IVB interventions compared to laser at 3 weeks.
There was significant heterogeneity amongst the trials: 65%-81% for the assessment of visual acuity and 49%-73% for CMT. Despite the high I 2, results were pooled and reported, as examination of the forest plot indicated that the individual trial results were consistent in the direction of the effect (ie, the mean difference, standard deviation and confidence intervals largely fell on the side of the null line favoring the intervention).
Subgroup analysis and assessment of publication bias could not be preformed due to small study numbers and data set. Meta-regression may be preformed in future to group the differing interventions in the Cunningham 21 and Scott 22 studies compared to a control group once data becomes available.
The pooled trend favors intervention using anti-VEGF to increase visual acuity and encourage CMT changes. Furthermore, trial quality was found to be better among those showing an improvement of BCVA and CMT using anti-VEGF.
Complications
There were no significant increases in complications reported among the interventions trialed. Complications associated with intravitreal injections, including ocular hypertension, were noted in a few studies. All trials noted to have ocular hypertension comment of successful treatment of increased IOP. Table 5 shows a summary of included study adverse events.
Discussion
In this systematic review of randomized controlled trials our meta-analysis has shown that anti-VEGF alone or in combination with triamcinolone is effective in the treatment of diabetic macular edema with an improved change in BCVA and CMT. Over with the treatment duration ranging from 12 to 36 weeks the initial analysis has shown a short-term benefit for the intervention and available information of adverse effects does not suggest potentially vision threatening complications with intravitreal injections.
Only the three trials included in the meta-analysis were of good methodological quality. There is no direct evidence comparing different types of anti-VEGF therapies so far published. The Scott et al 22 trial was conducted by a pharmaceutical company, thus has potential for bias due to conflict of interest. As mentioned above, we were also unable to use this trial in the meta-analysis due to the presentation of data Anti-VEGF for diabetic macular edema Dovepress submit your manuscript | www.dovepress.com Dovepress using medians and interquartile ranges. Our assumption was that the outcome distributions were skewed.
Cunningham et al 21 used three differing doses of IVP compared to a control. We were unable to scrutinize these interventions together in the same analysis as the same group of control subjects would have been entered twice. Hence, three separate analysis tables were calculated, each representing a different dose, from this trial. Future meta-regression to pool these groups may be performed.
Paccola et al 24 suggest intravitreal triamcinolone has a significant benefit in visual acuity over intravitreal bevacizumab. There was also a significant reduction in CMT in the intravitreal triamcinolone group at week 24 (P = 0.024), with similar results for visual acuity compared with IVB. Analysis of IVB was not performed to control so, although a benefit was anecdotally noted to improve visual acuity and CMT from baseline, this provides no significance statistically.
Subgroup analysis was not performed due to the limited number of studies. Similarly, assessment of publication bias was not performed due to the limited number of studies included in meta-analysis. Future inclusion of more clinical trials is needed for meaningful subgroup analysis including assessment of publications bias.
Quality of life and economic data were not available in any of the included studies making it is difficult to assign meaning to LogMAR changes in visual acuity. However, the trend is favorable towards intervention with regards to improvement of vision and perhaps slowing further progression of disease and its associated morbidity. Reduction in macular thickness, especially in regards to CMT, is considered a mechanism for visual improvement in the treatment of macular edema. Therefore, a corresponding reduction in CMT would be expected if there was a trend towards vision improvement. This is confirmed in the analysis where the intervention using anti-VEGF favored CMT improvement.
As current treatment is directed at stabilizing or reducing vision loss, an important finding is that there were no significant increases in complications among the interventions.
The results were limited by heterogeneity in the included trials. The difference in the intervention doses and duration of treatment contributed to this. A strength within the studies is that the exact definition and measurement of outcomes were fairly consistent and our pooled results should not be biased due to misclassification. The limited data for the Scott et al 22 study made it difficult to quantify the trial results concerning the effect of the intervention in a meaningful way.
Overall, most studies show a promising trend towards benefits in visual acuity and central macular thicken with use of anti-VEGF. Excluded studies continue to confirm this trend for most patients, although subgroups of patients with DME with ischemia were found to have a negative outcome.
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Conclusion
Strict glycemic and blood pressure control are still the hallmarks of prevention and progression of diabetic macular edema. The ETDRS brought laser therapy into consideration for mainstream use for diabetic macular edema with some modest benefit to visual acuity evidenced. 6 Anti-VEGF was associated with an improvement in visual acuity and CMT in our analysis. Trials studied were all of a short duration and there were no long-term follow-up studies found. There was no evidence found comparing the different types of anti-VEGF. The use of anti-VEGF is promising to improve visual acuity and CMT caused by diabetic macular edema. Further trials are being conducted, at present, with ongoing follow-up studies to assist in determining overall long-term benefit. The Appendix outlines some of the characteristics of these ongoing studies.
Implications for future research
The five studies in included in our report dealt primarily with persistent or refractory diabetic macular edema and raised issues including the duration of intervention, dosage, timing of repeats and follow-up, and the role of combination therapy with intravitreal triamcinolone in relationship to control or laser therapy. The question arises whether treatment 
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should be reserved for just this chronic or refractory group of patients or introduced during earlier stages of diabetic macular edema. Economic and quality of life data need to be considered, as well as further quantitative analysis of overall effects of complications. Long-term, follow-up studies with considerations for adverse effects need to be quantified and documented to provide a better understanding of risk benefits for patients with diabetic macular edema. Title: Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial Methods: Study design: RCT Method of randomization: Using computer generated random lists a random block permutation was performed with block lengths varying randomly (3,6) Number of randomized: 115 DME eyes (41 eyes in anti IVB arm, 37 eyes in the IVB/IVT arm and 37 eyes in the control arm.) Method of allocation concealment: no data Outcome assessor masking: Adequately masked Study duration: 24 weeks Losses to follow-up: One patient died in the control group during the study period. Intention to treat analysis: performed Participants: Inclusion criteria: Clinically significant macular edema unresponsive to previous macular laser with the last session being more than three months prior. Exclusion criteria: visual acuity 20/40, history of cataract surgery within the past 6 months, prior intraocular injection or vitrectomy, glaucoma or ocular hypertension, Proliferative diabetic retinopathy with high risk characteristics, vitreous hemorrhage, significant media opacity and presence and traction on the macula. Monocular patients, pregnant patients and those with a serum creatinine of 3 mg/100 were excluded. Type of DME: CSME Prior laser treatment: All participants Age: 59.7 ± 8.3 Comparability of baseline characteristics: groups were matched for age, sex, baseline visual acuity, hypertension, smoking history, stage of diabetic retinopathy, number of previous laser sessions at the macula and history of PRP (P  0.05) Treatment group were not matched for CMT which was lower in the control group compared to the other two groups (P  0.05). 
Interventions
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275 µm and no history of treatment for DME at any time within the prior 3 months. Exclusion criteria: Only one eye included in the study. Type of DME: retinal thickening due to DME involving the center of the macula Prior laser treatment: no laser treatment within 3 months of study starting time. Age: 65 Intervention: Test intervention: 1.25 mg of IVB at baseline and at 6 weeks; 2.5 mg of IVB at baseline and at 6 weeks; 1.25 mg of IVB at baseline; 1.25 mg of IVB at baseline and 6 weeks plus photocoagulation at 3 weeks. Title: Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular edema (IBEME) study Methods: Study design: RCT Method of randomization: no data Number of randomized: 28 eyes randomized 13 eyes IVB arm 13 eyes in IVT arm two losses Method of allocation concealment: no data Outcome assessor masking: Adequately masked for OCT, fluorescein angiography and fundus assessment were performed by two retina specialists who were aware of the treatment assignment. Study data were collected and interpreted and analyzed by two other masked investigators. Losses to follow-up: two patients missed two consecutive treatments Intention to treat analysis: not performed Participants: Inclusion criteria: Refractory DME (defined herein as the presence of clinically significant macula edema as per ETDRS criteria by biomicroscopic evaluation which had persisted despite at least one session of macula laser photocoagulation performed at least 3 months earlier). clinically significant DME according to ETDRS study, a minimum follow-up time of 3 months and recent fluorescein angiography within two weeks before treatment. All three criteria needed to be met. Exclusion criteria: intraocular surgery, including cataract extraction, laser treatments including panretinal photocoagulation, posterior capsulotomy, or focal/grid macular photocoagulation, within 6 months before the treatment and the presence of comorbid ocular conditions that might affect VA. Type of DME: CSME Prior laser treatment: greater than 6 months previously Age: ischemic group 65, nonischemic group 63.4 
Characteristics of ongoing studies Kriechbaum
Title: A randomized, double-masked study with Intraocular bevacizumab (Avastin ® ) compared with intraocular triamcinolone (Volon A ® ) in patients with clinical significant diabetic macular edema Method: randomized double blind trial Intervention: 2.5 mg IVB compared to 8 mg IVT Inclusion criteria: patients with diabetic macular edema with center involvement of CMT (macular edema) of at least 300 microns in the central subfield as measured by OCT; best-corrected visual acuity, using ETDRS charts, of 20/25 to 20/400 (Snellen equivalent) in the study eye; patients with decrease in vision in the study eye due to foveal thickening from diabetic macular edema and not to other causes, in the opinion of the investigator; patients without a necessity for panretinal laser photocoagulation for at least 3 months after study inclusion Exclusion criteria: a condition that would preclude a patient for participation in the study in opinion of investigator, eg, unstable medical status including glycemic control and blood pressure. History of systemic corticosteroids within 3 months prior to randomization or topical, rectal, or inhaled corticosteroids in current use more than 3 times per week. Prior/concomitant treatment: macular laser photocoagulation, panretinal laser photocoagulation within the past 3 months, previous treatment with intravitreal or sub-Tenon triamcinolone within the past 3 months in the study eye, previous participation in clinical trial involving antiangiogenic drugs (pegaptanib sodium, ranibizumab, anecortave acetate, protein kinase C inhibitor, etc), history of submacular surgery or other surgical intervention for diabetic macular edema in the study eye diabetic retinopathy characteristics, high risk proliferative diabetic retinopathy in the study eye without complete panretinal lasercoagulation and having a risk for intravitreal bleeding, concurrent ocular conditions, active intraocular inflammation (grade trace or above) in either eye, vitreomacular traction in the study eye evident by OCT, ocular disorders in the study eye including retinal vascular occlusion, retinal detachment, macular hole, choroidal neovascularization, intraocular surgery (including cataract surgery, YAG laser capsulotomy) in the study eye within 3 months preceding Day 0, uncontrolled glaucoma in the study eye (defined as IOP 25 mmHg despite treatment with antiglaucoma medication), history of glaucoma filtration surgery, corneal transplantation in the study eye concurrent systemic conditions, history of myocardial infarction (in anamnesis or signs in ECG), history of congestive heart failure, history of stroke or transient ischemic attacks, significant abnormalities on laboratory testing (signs on failure of kidney, liver disease), premenopausal women not using adequate contraception and pregnant or nursing women and history of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use an investigational drug or that might affect interpretation of the results of the study or render the subject at high risk for treatment complications. Primary outcome measure: BCVA and CMT Secondary measures: structural mechanisms of DME by fluorescein angiography. Data source: online clinical trials.gov register Funding source: Medical University of Vienna Country: Austria Jorge Title: Intravitreal bevacizumab versus intravitreal triamcinolone acetonide for refractory diabetic macular edema Methods: randomized controlled trial Intervention: 2.5 mg IVB compared to IVT 4 mg Inclusion criteria: refractory diffuse DME (defined herein as clinically significant DME (by biomicroscopic evaluation) unresponsive to focal laser photocoagulation (performed at least 3 months before evaluation) and generalized breakdown of the inner blood-retina barrier with diffuse fluorescein leakage involving the foveal center and most of the macular area on fluorescein angiography), and Snellen logarithm of minimum angle of resolution (LogMAR) BCVA equivalent of 20/40 or worse, and CMT greater than 300 µm on OCT. Exclusion criteria: aphakic or pseudophakic eyes, glycosylated hemoglobin (HbA1C) rate above 10%, history of glaucoma or ocular hypertension, loss of vision as a result of other causes, systemic corticoid therapy, history of thromboembolic event (including myocardial infarction or cerebral vascular accident), major surgery within the prior 6 months or planned within the next 28 days, uncontrolled hypertension (according to guidelines of the seventh report of the joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure, 16 known coagulation abnormalities or current use of anticoagulative medication other than aspirin, severe systemic disease. 
Novartis
Title: A randomized, double-masked, multicenter, Phase II study assessing the safety and efficacy of two concentrations of ranibizumab (intravitreal injections) compared with nontreatment control for the treatment of diabetic macular edema with center involvement Method: treatment, randomized, double-bnlind, placebo control, parallel assignment, safety/efficacy study. Inclusion criteria: diabetic macular edema with center involvement in at least one eye, Type 1 or type 2 diabetes mellitus diagnosed 2 years prior to screening, and laser photocoagulation in the study eye can be withheld for at least 3 months after randomization. Exclusion criteria: patients with uncontrolled systemic or ocular diseases, have any history of any intraocular surgery in the study eye within the past 6 months preceding screening and conditions that require chronic concomitant therapy with systemic or topical ocular corticosteroids. 
Lim
Title: Avastin in the treatment of macular edema and uveitis Method: nonrandomized trial Intervention: 1.25 mg IVB Inclusion criteria: Clinically significant macular edema secondary to diabetes involving the fovea in one or both eyes that has been refractory to previous standard treatments (eg, laser) where local steroid therapy is contraindicated (eg, pre-existing glaucoma or steroid responder) or ineffective, OR 3. Uveitic cystoid macular edema in one or both eyes that has either been unresponsive to standard treatment (including intravitreal triamcinolone) or where further local steroid treatment is relatively contraindicated (eg, pre-existing glaucoma or steroid responder) or ineffective, OR 4. Subfoveal or juxtafoveal choroidal neovascularization (CNV) secondary to uveitis in one or both eyes, best-corrected visual acuity in the affected eye(s) = 6/12 or worse 5. Subjects must have signed the informed consent form. Exclusion criteria: Loss of vision due to other causes (eg, myopic macular degeneration), surgical intervention in the study eye within 2 months preceding recruitment, significant macular ischemia, no useful vision in fellow eye, known allergies to bevacizumab or ranibizumab, active ocular infection (eg, conjunctivitis, keratitis), intercurrent severe disease such as septicaemia, history of other systemic disease(s) that, in the opinion of the investigator, may render the subject at a high risk for treatment complications, any condition which would affect follow-up or photographic documentation (eg, geographical, psycho-social, media opacities), unwillingness or inability to give informed consent, under age 18, pregnant or lactating women, and premenopausal women. 
